டோயாமா இரசாயன இணை லிமிடெட் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from டோயாமா இரசாயன இணை லிமிடெட். Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In டோயாமா இரசாயன இணை லிமிடெட் Today - Breaking & Trending Today

Rejection Of Favipiravir Patent In Thailand - Was Was There A Better Way? - Intellectual Property


To print this article, all you need is to be registered or login on Mondaq.com.
On 5 May 2021, the Department of Intellectual Property (DIP) of
Thailand rejected a Thai patent application for a granulated powder
tablet containing 6-fluoro-3-hydroxy-2-pyrazinecarboxamide, also
known as Favipiravir, which is a drug used to treat viral
infections including COVID-19. Favipiravir has been used in many
countries including Thailand to treat COVID-19 patients. 
With the spiking numbers of COVID-19 infections, demand for
Favipiravir has soared with fears of shortage. As Favipiravir can
currently only be imported into the country, Thailand aims to
establish a production hub for the Favipiravir tablets to meet ....

United States , Government Pharmaceutical Organization , Public Health Ministry , Health Organization , Department Of Intellectual Property , Toyama Chemical Co Ltd , Office Action , Intellectual Property , Cooperation Treaty , Rejection Order , Patent Board , Thai Patent , Rejection Of Favipiravir Patent In Thailand Was Therea Better Way , Coronavirus Covid 19 , Operational Impacts And Strategy , Life Sciences , Food And Drugs Law , ஒன்றுபட்டது மாநிலங்களில் , அரசு மருந்து ஆர்கநைஸேஶந் , பொது ஆரோக்கியம் அமைச்சகம் , ஆரோக்கியம் ஆர்கநைஸேஶந் , துறை ஆஃப் அறிவுசார் ப்ராபர்டீ , டோயாமா இரசாயன இணை லிமிடெட் , அலுவலகம் நடவடிக்கை , அறிவுசார் ப்ராபர்டீ , ஒத்துழைப்பு ஒப்பந்தம் ,

Dr. Reddys and GRA announces Avigan Pivotal Studies Update


Posted on
895
Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY along with its subsidiaries together referred to as “Dr. Reddy’s”) and Global Response Aid FZCO (GRA) today announced the termination of Avigan Trial Study conducted in Kuwait focused on moderate to severe COVID patients in a hospital setting.
The hospitalized patient study, conducted in Kuwait, on moderate to severe patients was one of the studies in the overall clinical program for Avigan, spanning the spectrum of Asymptomatic to severe cases of COVID in both outpatient and in-patient setting. The Phase-III study, being conducted in an outpatient setting on patients with mild to moderate symptoms in North America by Dr. Reddy’s, in partnership with Appili Therapuetics and Global Response Aid, shall continue. ....

United Arab Emirates , United States , Appili Therapuetics , Exchange Commission , Holdings Corporation , Services Active Ingredients , Reddy Laboratories Ltd , Toyama Chemical Co Ltd , Global Response Aid , Avigan Trial Study , North America , Pharmaceutical Services , Active Ingredient , Global Generics , Proprietary Products , Annual Report , Appili Therapeutics , ஒன்றுபட்டது அரபு அமீரகங்கள் , ஒன்றுபட்டது மாநிலங்களில் , பரிமாற்றம் தரகு , ஹோல்டிங்ஸ் நிறுவனம் , சேவைகள் செயலில் பொருட்கள் , சிவப்பு ஆய்வகங்கள் லிமிடெட் , டோயாமா இரசாயன இணை லிமிடெட் , உலகளாவிய பதில் உதவி , வடக்கு அமெரிக்கா ,